Pfizer's US $150 million acquisition of bamboos with a maximum transaction price of 495 million

Source: Wall Street Journal August 5, 2016 Pfizer said it would offer $150 million or more to bambootherapeutics, a biotech company engaged in gene therapy development, to expand the performance of the pharmaceutical giant in gene therapy and other experimental fields, according to the Wall Street Journal In addition, Pfizer will pay up to $495 million to Pfizer for the acquisition and other terms Bamboos therapeutics, headquartered in Chapel Hill, North Carolina, USA, is a closed holding company Bamboos is currently engaged in the development of drugs for the treatment of neuromuscular diseases and central nervous system disorders Pfizer also said in a statement that it will take over the treatment under development in bamboos, which has not yet been applied to the human body, as well as its manufacturing facilities In addition to the above $150 million purchase price, Pfizer will pay an additional $495 million to bamboos if the gene therapy developed by bamboos can pass various tests and meet regulatory standards.